Improving Disease Burden in Myelofibrosis: Changing the Natural History of the Disease THE KREMYANSKAYA ET AL ARTICLE REVIEWED

被引：0

作者：

Mesa, Ruben A. ^{[1
]}

机构：

[1] Mayo Clin, Ctr Canc, Div Hematol Oncol, Acute & Chron Leukemias Program, Phoenix, AZ USA

来源：

ONCOLOGY-NEW YORK | 2013年 / 27卷 / 07期

关键词：

PROGNOSTIC SCORING SYSTEM; INTERNATIONAL WORKING GROUP; RUXOLITINIB; THERAPY; TRIAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：715 / 716

页数：2

共 6 条

[1] Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al Reply
Lubrano, Ennio
Spadaro, Antonio
ARTHRITIS CARE & RESEARCH, 2012, 64 (08) : 1269 - 1270
[2] Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et al
Dervieux, Thierry
Kremer, Joel
ARTHRITIS AND RHEUMATISM, 2010, 62 (08): : 2559 - 2560
[3] The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Orebro, Sweden 1963-2005
Zhulina, Yaroslava
Udumyan, Ruzan
Tysk, Curt
Montgomery, Scott
Halfvarson, Jonas
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (03) : 304 - 313
[4] Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: comment on the article by Saag et al
van Tuyl, L. H. D.
Lems, W. F.
Voskuyl, A. E.
Dijkmans, B. A. C.
Boers, M.
Kerstens, P. J. S. M.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (01): : 141 - 142
[5] Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the Abatacept versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate study: comment on the article by Fleischmann et al
Curtis, Jeffrey R.
Wright, Grace C.
Strand, Vibeke
Davis, Charles S.
Hitraya, Elena
Sasso, Eric H.
ARTHRITIS & RHEUMATOLOGY, 2017, 69 (04) : 863 - 865
[6] Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: Comment on the article by Singh et al
Conn, Doyt L.
ARTHRITIS CARE & RESEARCH, 2012, 64 (10) : 1622 - 1623

← 1 →